Congress wouldn’t allow Medicare to pay for benzodiazepines such as Xanax and Ativan until 2013. Now, the medications are among the most prescribed in its drug program.
The move follows an investigation showing that Medicare did little to find dangerous prescribing by doctors to seniors and the disabled. It is also part of the government’s new push to bring transparency to taxpayer-supported medical care.
Medicare’s spending on drugs to treat hepatitis C soared more than 15-fold from 2013 to 2014 as new breakthroughs came to the market, according to previously undisclosed federal data. The drugs cure the disease, but taxpayers are footing the bill.
The findings by the inspector general of the U.S. Department of Health and Human Services complement a recent review that found many doctors bill for services very differently than their peers.